[1] TRAYNOR K. FDA approves tesamorelin for HIV-related lipodystrophy[J]. Am J Health Syst Pharm， 2010， 67(24)： 2082.
[2] FDA. Label approved on 11/10/2010 (PDF) for EGRIFTA[EB/OL]. http：//www.accessdata.fda.gov/drugsatfda_docs/label/2010/022505s000lbl.pdf
[3] FALUTZ J， POTVIN D， MAMPUTU J C， et al. Effects of tesamorelin， a growth hormone-releasing factor， in HIV-infected patients with abdominal fat accumulation： a randomized placebo-controlled trial with a safety extension[J]. J Acquir Immune Defic Syndr， 2010， 53(3)： 311-322.
[4] FALUTZ J， ALLAS S， MAMPUTU J C， et al. Long-term safety and effects of tesamorelin， a growth hormone-releasing factor analogue， in HIV patients with abdominal fat accumulation[J]. Aids， 2008， 22(14)： 1719-1728.
[5] Side effects and complications. Tesamorelin-results from Phase III[J]. Treatment Update， 2007， 19(3)： 6-7.